Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second phase III study of ALLN-177 enteric hyperoxaluria

Trial Profile

Second phase III study of ALLN-177 enteric hyperoxaluria

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs Reloxaliase (Primary)
  • Indications Hyperoxaluria
  • Focus Registrational; Therapeutic Use
  • Acronyms URIROX-2
  • Sponsors Allena Pharmaceuticals
  • Most Recent Events

    • 02 Jan 2019 According to an Allena Pharmaceuticals media release, this trial was initiated in the fourth quarter of 2018.
    • 02 Jan 2019 Status changed from planning to recruiting, according to an Allena Pharmaceuticals media release.
    • 02 Jan 2019 According to an Allena Pharmaceuticals media release, the company reached an agreement with the U.S. FDA regarding the design of Phase III program, under which the FDA agreed that, if positive, biomarker data on 24-hour UOx excretion in URIROX-1 and URIROX-2 would be used for a BLA filing for accelerated approval of reloxaliase in enteric hyperoxaluria and that patients would continue in URIROX-2 to confirm clinical benefit during the long-term follow-up phase of the trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top